HypeCheck
← All Ingredients Anti Inflammatory

Last verified: today

Japanese Knotweed

Also known as: Polygonum cuspidatum, Reynoutria japonica, Fallopia japonica, Hu Zhang, resveratrol source, polydatin source

Evidence under review. — Not yet rated

Plant rich in resveratrol. Lab studies show antioxidant and antiviral activity, but no human trials exist.

  • What it does

    Japanese Knotweed is an invasive plant whose roots and leaves are rich in polyphenols, especially resveratrol and polydatin. Lab studies show its extracts can neutralize free radicals, protect red...

  • Evidence quality

    Evidence base hasn't been formally rated yet. See research below.

  • Clinical dose

    No established dose (insufficient research data)

See full breakdown ↓ Methodology →

What the Science Says

Japanese Knotweed is an invasive plant whose roots and leaves are rich in polyphenols, especially resveratrol and polydatin. Lab studies show its extracts can neutralize free radicals, protect red blood cells from oxidative damage, and inhibit SARS-CoV-2 in cell cultures. It is also used in some herbal protocols for Lyme disease symptoms, though evidence for that use is limited to in-vitro antimicrobial data with no human clinical trials.

What It Doesn't Do

Not proven to treat or prevent any human disease. No human clinical trials back any health claim. Lab results in cells and animals don't automatically translate to benefits in people. Not a proven Lyme disease treatment. Don't confuse 'contains resveratrol' with 'proven to work like resveratrol in humans.'

Evidence-Based Benefits

Extracts protect red blood cells from free radical damage in lab studies.

Weak Evidence

Effective at: No established dose

Rhizome bark extract inhibited SARS-CoV-2 in cell culture at specific concentrations.

Weak Evidence

Effective at: No established dose

Shows limited in-vitro activity against Borrelia, the bacteria linked to Lyme disease.

Weak Evidence

Effective at: No established dose

Absorption & Bioavailability

Unknown — no human pharmacokinetic data in the provided studies. Resveratrol (its key compound) is generally known to have poor oral bioavailability, but this was not assessed in the provided papers.

Red Flags to Watch For

  • Zero human clinical trials in the provided evidence base — all findings are from cell cultures or animal models
  • Widely marketed for Lyme disease despite only in-vitro antimicrobial data and no in-vivo or clinical evidence
  • Resveratrol content varies widely between products; no standardization data provided
  • High doses showed cytotoxic effects in cell studies — more is not necessarily better
  • Invasive plant species; quality and contamination controls in commercial extracts are not well studied

Research Sources

  • PubMed
  • NIH DSLD

This information is for educational purposes only and is not medical advice. Always consult a healthcare professional before starting any supplement regimen. Last updated: 2026-05-25